Gerald Greer, MD
Clinical Cardiac Electrophysiology · Little Rock, ARNPI 1811943400
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,450 of the $41,352 with a category attached, or 64.0%. Lundbeck LLC accounts for 72.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $25,372 and has fallen 90.6% since, to $2,385 in 2025.
Across 412 payments — averaging $100.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$30K
- Abbott$5K
- Amgen$1K
- Novartis$1K
- CSL Behring$972
- Johnson & Johnson$738
- plus $3K from 23 others
Across 91 payments — averaging $5201.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$371K
- Amgen$51K
- H. Lundbeck A S$27K
- AstraZeneca$10K
- Regeneron$9K
- Astrazeneca UK Limited$3K
- plus $2K from 3 others
What the payments were for
- Speaking & faculty fees$26,45064%
- Travel & lodging$8,47720%
- Food & beverage$6,37515%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 38 | $29,890 |
| Abbott | 19 | $4,839 |
| Amgen | 34 | $1,213 |
| Novartis | 87 | $1,009 |
| CSL Behring | 5 | $972 |
| Johnson & Johnson | 58 | $738 |
| E.r. Squibb & Sons, L.L.C. | 44 | $537 |
| Pfizer | 30 | $370 |
| Medtronic(2 entities) | 6 | $363 |
| AstraZeneca | 13 | $185 |
| Sanofi-aventis U.S. LLC | 12 | $181 |
| Boston Scientific | 10 | $157 |
| Merck | 10 | $139 |
| Boehringer Ingelheim | 8 | $121 |
| Alnylam Pharmaceuticals Inc. | 6 | $104 |
| Philips North America LLC | 4 | $87 |
| Baxter Healthcare | 3 | $83 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $76 |
| Bardy Diagnostics, Inc. | 4 | $51 |
| Irhythm Technologies, Inc. | 3 | $50 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Bridgebio Pharma, Inc. | 2 | $33 |
| Altathera Pharmaceuticals LLC | 1 | $19 |
| Atricure, Inc. | 1 | $18 |
| Akcea Therapeutics, Inc. | 1 | $18 |
| Cardiva Medical, Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NORTHERA$29,578
- AVEIR$4,474
- Reveal LINQ$130
How this compares
$41,352 in reported general payments places this provider in the 70th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
See all clinical cardiac electrophysiology providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 627 | $456,989 |
| VyndamaxTafamidis | 13 | $293,024 |
| EntrestoSacubitril/Valsartan | 203 | $156,527 |
| XareltoRivaroxaban | 100 | $76,520 |
| Droxidopa | 54 | $54,981 |
| Midodrine Hcl | 501 | $38,816 |
| MultaqDronedarone Hcl | 37 | $29,524 |
| Repatha SureclickEvolocumab | 24 | $22,401 |
| Praluent PenAlirocumab | 23 | $10,789 |
| SotalolSotalol Hcl | 373 | $8,306 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 33 | $5,500 |
| Clonidine | 68 | $4,458 |
| Pindolol | 21 | $3,836 |
| Fludrocortisone Acetate | 206 | $3,706 |
| Potassium Chloride | 144 | $3,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $370 | $750,013640 claims |
| NovartisEntresto | $1,009 | $156,527203 claims |
| Johnson & JohnsonXarelto | $738 | $76,520100 claims |
| Sanofi-aventis U.S. LLCMultaq | $181 | $29,52437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
Other clinical cardiac electrophysiology in Little Rock
- Monica LoLittle Rock$190K
- Sudarone ThihalolipavanLittle Rock$77K
- Prabhat HebbarLittle Rock$75K
- Risheek KaulLittle Rock$38K
- Michael LoguidiceLittle Rock$29K
- Breck SandvallLittle Rock$23K
- Brian NorrisLittle Rock$18K
- Thomas WallaceLittle Rock$14K
- Subodh DevabhaktuniLittle Rock$9K
- van de BruynLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.